Filipijnen - Engels - FDA (Food And Drug Administration)

each kit contains: pyrazinamide 250 mg/ 5ml suspension (pyzather) rifampicin 200 mg/ 5 ml suspension (fampisec) isoniazid 200 mg/5 ml syrup (bacciter forte) - suspension/suspension/syrup - each kit contains: pyrazinamide 250 mg/ 5ml suspension (pyzather) rifampicin 200 mg/ 5 ml suspension (fampisec) isoniazid 200 mg/5 ml syrup (bacciter forte)

Australië - Engels - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethambutol hydrochloride, quantity: 400 mg - tablet, film coated - excipient ingredients: ethylcellulose; magnesium stearate; titanium dioxide; polyethylene glycol monomethyl ether; povidone; purified talc; propylene glycol; hypromellose; maize starch; colloidal anhydrous silica - ethambutol lupin is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculous meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculosis of the skin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjunction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies.,in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs ? ethambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 months. for example:,? ethambutol plus isoniazid plus rifampicin; or ? ethambutol plus isoniazid plus streptomycin,then continuing with a two drug regimen such as,? ethambutol plus isoniazid; or ? ethambutol plus rifampicin.,in patients who have received previous antituberculosis therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment cases ethambutol lupin should be combined with at least one of the second-line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculosis drugs used with ethambutol have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. alternating drug regimens have also been utilised.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethambutol hydrochloride, quantity: 400 mg - tablet, film coated - excipient ingredients: maize starch; propylene glycol; hypromellose; colloidal anhydrous silica; purified talc; povidone; magnesium stearate; titanium dioxide; ethylcellulose; polyethylene glycol monomethyl ether - ethambutol lupin is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculous meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculosis of the skin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjunction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies.,in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs ? ethambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 months. for example:,? ethambutol plus isoniazid plus rifampicin; or ? ethambutol plus isoniazid plus streptomycin,then continuing with a two drug regimen such as,? ethambutol plus isoniazid; or ? ethambutol plus rifampicin.,in patients who have received previous antituberculosis therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment cases ethambutol lupin should be combined with at least one of the second-line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculosis drugs used with ethambutol have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. alternating drug regimens have also been utilised.

Zuid-Afrika - Engels - South African Health Products Regulatory Authority (SAHPRA)

pharma dynamics (pty) ltd - tablet - 75,0 mg - each tablet contains isoniazid 50,0 mgrifampicin 75,0 mg

India - Engels - Central Drugs Standard Control Organization

biological e. - rifampicin+pyrazinamide+isoniazid,ethambutol - tab - 225+750mg+150mg(2t),800;mg(1t) - 3t pack

Ierland - Engels - HPRA (Health Products Regulatory Authority)

sandoz gmbh - rifampicin isoniazid pyrazinamide ethambutol dihydrochloride - film coated tablet - 150/75/400 milligram

Ierland - Engels - HPRA (Health Products Regulatory Authority)

sandoz gmbh - rifampicin isoniazid - coated tablets - 300/150mg milligram

Zuid-Afrika - Engels - South African Health Products Regulatory Authority (SAHPRA)

sanofi-aventis south africa (pty) ltd - tablet - see ingredients - each tablet contains ethambutol 275,0 mgisoniazid 75,0 mgpyrazinamide 400,0 mgrifampicin 150,0 mg

Ierland - Engels - HPRA (Health Products Regulatory Authority)

sandoz gmbh - rifampicin isoniazid - film coated tablet - 150/75 milligram

India - Engels - Central Drugs Standard Control Organization

novartis - rifampicin,pyrazinamide,isoniazid - tab - 225,750,150;mg - 100